Naveen Pemmaraju, MD, provides an overview of myelofibrosis, including a comparison of primary and secondary myelofibrosis and the risk stratification.
The Phase 2 REFINE Trial: Ruxolitinib Plus Navitoclax for Myelofibrosis
Dr Naveen Pemmaraju explains the relationship of the JAK/STAT pathway to myelofibrosis and the molecular mutations he looks for with biomarker testing.
Naveen Pemmaraju, MD, describes the currently available treatment options for patients with myelofibrosis.
A review of the study design and key efficacy and safety outcomes of the REFINE trial studying ruxolitinib plus navitoclax treatment in myelofibrosis.
Naveen Pemmaraju, MD, talks about the potential implications of the phase II REFINE trial on the myelofibrosis treatment paradigm.
Dr Naveen Pemmaraju discusses exciting potential treatment options in myelofibrosis and some unmet needs and ongoing challenges in the treatment landscape.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Insurance Delays and Travel Strain CAR T Referral in Early Relapsed Myeloma
2
NCCN Guidelines Add Cosibelimab for Locally Advanced CSCC
3
Real-World Data for Darolutamide vs Abiraterone Triplet Therapy in mHSPC
4
Oncologists Debate Role of On-Body Injector for Transplant-Ineligible Myeloma
5